Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series
- 1Department of Internal Medicine, Klinikum Aschaffenburg, Aschaffenburg, Germany
- 2Medizinische Poliklinik, University of Würzburg, Würzburg, Germany
- 3Gesundheitszentrum Süd, Vienna, Austria
- 4Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
- 5Institute of Pathology, University of Würzburg, Würzburg, Germany
- Correspondence to:
Professor W Fischbach
Medizinische Klinik II, Klinikum Aschaffenburg, Am Hasenkopf, D-63739 Aschaffenburg, Germany;
- Accepted 5 August 2003
Background:Helicobacter pylori plays a decisive role in the pathogenesis of gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT), and eradication therapy has become a widely accepted initial treatment of stage I disease.
Objective: To determine the long term outcome of patients undergoing exclusive H pylori eradication therapy.
Design: A prospective series of patients with newly diagnosed marginal zone B cell lymphoma of MALT.
Setting: Multicentre study in Germany and Austria.
Patients: Ninety five patients; 90 of these (five lost to follow up) with a mean age of 54.3 (27–85) years were followed up for at least 12 months.
Intervention: Complete staging work up revealing stage I disease and H pylori infection. Patients received triple therapy (OMC: omeprazole 20 mg twice daily, metronidazole 400 mg twice daily, and clarithromycin 250 mg twice daily; or OAC: omeprazole 20 mg twice daily, amoxycillin 1000 mg twice daily, and clarithromycin 500 twice daily) for one week.
Results: Median follow up was 44.6 (12–89) months. H pylori was successfully eradicated in 88 patients (98%); in two patients eradication therapy failed. Long term outcome was characterised by complete regression of lymphoma in 56 patients (62%), minimal residual disease in 17 patients (18%), partial remission in 11 patients (12%), no change in four patients (4%), and progressive disease in two patients (2%). Four patients with complete remission relapsed after 6, 8, 8, and 15 months, one revealing reinfection by H pylori. Regression rate was higher in stage I1 disease compared with stage I2, as diagnosed by endoscopic ultrasound.
Conclusion: The majority of patients with low grade gastric MALT lymphoma treated by exclusive H pylori eradication have a favourable long term outcome, offering a real chance of cure.
- MALT, mucosa associated lymphoid tissue
- OMC, omeprazole, metronidazole, and clarithromycin
- OAC, omeprazole, amoxycillin, and clarithromycin
- EUS, endoscopic ultrasound
Presented and published as an abstract at the Digestive Disease Week, Atlanta, May 2001.